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   박사과정은 저에게 또 하나의 목표였고 도전이었습니다. 학위를 
처음 시작하면서 느꼈던 많은 의문과 어려움은 3년이라는 시간이 
지난 지금에선 더욱 큰 이상적 목표가 되어 제 앞에 놓여져 있습
니다.  
그 동안의 수많은 좌절과 몇 번의 극복 과정 그리고 미래로의 
긍정적인 사고방식으로 오기까진 차라리 순탄치 못했던 박사과정
의 시간이 저에겐 퇴비가 되어 더 큰 역할을 해 주었던 것 같습니
다. 학문적 가르침 이상의 수많은 조언과 기회로 지금의 이 논문을 
쓸 수 있도록 길을 열어 주셨던 윤주헌 선생님께 저의 존경하는 
마음과 진심으로 감사하다는 말을 전해 드리고 싶습니다. 눈앞의 
결과만을 바라보며 쫓아가던 제가 조금이나마 학문적 가치의 방향
성을 이해할 수 있었던 것이 학위과정중의 가장 큰 성과라고 생각
합니다.   
이비인후과 내에서 저희 연구원들이 열심히 연구할 수 있도록 
자리를 지켜주시고 저의 논문이 완성될 때까지 많은 관심을 가져
주셨던 이정권 선생님께 깊이 감사 드립니다. 그리고, 저의 논문이 
완성될 때까지 끊임없는 퇴고와 실험적 조언으로 제 어려움을 대
신해 주셨던 박전한 선생님, 이재면 선생님, 그리고 윤호근 선생님
께 진심으로 감사 드립니다.  그 밖에 수많은 이비인후과 선생님들
과 동료 연구원들께 감사의 말을 전해드리고 싶습니다.  
저에게 지금까지 그리고 이 순간에도 가장 큰 관심과 사랑으로 
저를 지켜봐 주시고 믿음을 주시는 아버지, 어머님께 마음 깊이 감
사 드립니다. 이제 끝이 아닌 새로 시작하는 이 시점이 언젠가 있
을 멋진 인생의 결과들의 시작점이 되길 바라며, 이제 그 행로의 
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Mucins are high molecular weight proteins that are major components 
of mucus. Hypersecretion of mucus is a feature of several chronic 
inflammatory airway diseases. MUC8 is an important component of airway 
mucus, and its gene expression is up-regulated in nasal polyp epithelium. 
However, little is known about the mechanisms of MUC8 gene expression. 
We previously demonstrated that phorbol 12-myristate 13-acetate (PMA) 
treatment of the airway epithelial cell line NCI-H292 increases MUC8 gene 
 2 
expression. In this study, we sought to determine which signal pathway is 
involved in PMA-induced MUC8 gene expression. This study found that 
MUC8 gene expression is modulated by the protein kinase C and mitogen 
activating protein/ERK kinase (MAPK) pathways. PD98059 (a MEK-1 
inhibitor) or ERK1/2 siRNA and RO31-8200 (PKC inhibitor) significantly 
suppressed activator protein-2alpha (AP2α) as well as MUC8 gene 
expression in PMA-treated cells. To verify the role f AP2α, we specifically 
knocked down the expression of AP2α with siRNA for AP2α. Significantly, 
knocking down of AP2α inhibited PMA-induced MUC8 gene expression. 
While dominant negative forms of AP2α decreased PMA-induced MUC8 
gene expression, an over-expression of wild type AP2α increased MUC8 
gene expression in NCI-H292 cells. In addition, we id ntified an AP2α 
consensus region on the MUC8 gene promoter. Furthermore, using lentiviral 
vectors for RNA interference in human nasal polyp epithelial cells, we 
confirmed an essential role for AP2α in MUC8 gene expression.  From 
 3 
these results, we conclude that PMA induces MUC8 gene expression 
through a mechanism involving PKC and MEK-ERK1/2- AP2α activation in 
human airway epithelial cells. 
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Ⅰ. INTRODUCTION  
 
Mucins are high molecular weight glycoproteins that are major 
components of the mucus. In the airway, virtually al forms of airway 
inflammation are associated with the overproduction of mucus, which can 
lead to airway obstruction. Mucins are responsible for the viscoelastic 
properties of secreted mucus and provide lubrication and protection for 
mucus membranes. Mucus hypersecretion is commonly observed in many 
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respiratory diseases such as rhinitis, sinusitis, otitis media, nasal allergy, 
chronic bronchitis, and cystic fibrosis. To date, 20 distinct mucin genes have 
been identified. The mucins are usually subdivided into two groups based on 
domain: the membrane-bound and secreted mucins. MUC2, MUC5AC, 
MUC5B, MUC6, MUC7, MUC9, and MUC19 are secreted mucins, and 
MUC1, MUC3, MUC4, MUC11, MUC12, MUC13, MUC17, MUC18, and 
MUC20 are membrane-bound mucins1-18. The other mucin genes, including 
MUC8, have not been fully characterized.  
MUC8 may be an important airway mucin, because its mRNA levels 
are up-regulated in middle ear effusions19, chronic sinusitis20, and 
endometrial adenocarcinomas21. In addition, because MUC8 protein is over-
expressed in polyp epithelium, it may be involved in chronic inflammation 
of the nasal mucosa. However, the mechanisms behind MUC8 gene 
expression during inflammation and the signal molecul s involved have not 
been fully elucidated.  
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In this study, we first observed that AP2α was over-expressed in nasal 
polyp epithelium. The 52-kDa transcription factor activator protein AP2α is 
a DNA-binding transcription factor, which regulates the expression of 
various genes and its activity is regulated by retinoic acid, cAMP, and 
phorbol esters22, 23. Several studies suggest that AP2α may control 
proliferation, apoptosis, and differentiation of mamary epithelial cells24, 25. 
In invasive carcinoma, AP2α expression in ductal epithelia is involved in the 
tumor process26.  
 Phorbol esters such as PMA have been reported to function as tumor 
promoters by modulating diverse cellular responses such as gene 
transcription, cellular growth and differentiation, programmed cell death, 
immune response, and receptor desensitization throug  protein kinase C 
(PKC) signaling pathways27, 28. PMA can substitute for diacylglycerol, the 
endogenous activator of PKC, and it has been used as a model of 
inflammatory stimulus to study the signaling mechanisms of mucins29-34. 
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PMA has been shown to upregulate several mucin genes, i cluding MUC2, 
MUC5B, and MUC5AC. However, a detailed analysis of the signaling 
pathways involved in PMA-induced up-regulation of MUC8 has not been 
performed.     
Previous studies have showed that MUC8 is clearly upregulated in 
nasal polyp epithelium35-37. In addition, inflammatory mediators such as IL-
1β, tumor necrosis factor-α (TNF-α), and prostaglandin E2 promote MUC8 
expression, suggesting that the mRNA level of MUC8 increases under 
inflammatory conditions. Recently, this study revealed that AP2α protein is 
also overexpressed in nasal polyp epithelium compared with normal nasal 
mucosa, indicating that this transcription factor might be important for 
regulating MUC8 gene expression. To explore the biochemical mechanisms 
involved in AP2α and MUC8 overexpression in nasal polyp cells, this study 
examined the functional significance of AP2α for MUC8 gene transcription.  
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We used PMA to evaluate the signaling mechanisms between PMA-
induced MUC8 and AP2α. We found that extracellular signal-regulated 
kinase mitogen-activated protein kinase (ERK MAPK) and AP2α are 
essential for PMA-induced MUC8 gene expression in NCI-H292 cells. 
These pathways provide insight into the molecular mechanisms of mucous 
hypersecretion and may open up novel targets for therapeutic intervention.  
Ⅱ. MATERIALS AND METHODS 
 1. Materials  
Anti-MUC8 antibody was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Anti phospho-p44/42 MAP kinase (Thr202/Tyr204) 
antibody, anti-phospho-p38 MAP kinase (Thr180/Tyr182) antibody, anti-
phospho-SAPK/c-Jun NH2-terminal kinase MAP kinase (Thr183/Tyr185) 
antibody, and anti-human AP2α antibody were purchased from Cell 
Signaling (Beverly, MA, USA). RO-31-8220, PD98059 and anti-α-tubulin 
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antibody were purchased from Calbiochem (San Diego, CA, USA). Anti-
phospho-MEK1 (pThr386) antibody was purchased from Sigma-Aldrich (St. 
Louis, MO, USA).  
 2. Cell culture  
Epithelia were isolated from scrapings of the inferior turbinate or nasal 
polyp. The epithelial cells were treated with 1% Pronase (Type XIV protease, 
Sigma-Aldrich Chemical Co., St. Louis, MO, USA) for 18 to 20 h at 4 °C. 
To remove fibroblasts, endothelial cells, and myoepith lial cells, isolated 
cells were placed in a plastic dish and cultured for 1 h at 37 °C. Isolated 
epithelial clusters were divided into single cells by incubating them with 
0.25% trypsin/EDTA. Passage-2, normal human nasal epithelial (NHNE) 
cells or human nasal polyp epithelial cells were seded in 0.5 ml of culture 
medium onto 24.5-mm, 0.45-µm pore size Transwell clar culture inserts. 
Cells were cultured in a 1:1 mixture of bronchial epithelial cell growth 
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medium (Clonetics, CA, USA) and Dulbecco's modified Eagle's medium 
(Invitrogen, San Diego, CA, USA) containing all supplements. The cultures 
were grown submerged for the first 9 days, during which time the culture 
medium was changed on day 1 and every other day thereaft r. The air-liquid 
interface (ALI) was created on day 9 by removing the apical medium and 
feeding the cultures only from the basal compartmen. The culture medium 
was changed daily after creation of an ALI. Cells were treated on 7 day after 
confluence for all experiment, indicating that primary cells were in a 
differentiated state at the time of treatment. The human mucoepidermoid 
pulmonary carcinoma cell line NCI-H292 was purchased from the American 
Type Culture Collection (CRL-1848, Manassas, VA, USA) and cultured in 
RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum 
(Invitrogen) in the presence of penicillin-streptomycin (Invitrogen) at 37 °C 
in a 5% CO2 humidified chamber.  
 3. Treatment of cells with PMA  
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NCI-H292 cells were seeded into 6-well plates, cultured for 24 hr to 
confluency, and serum-starved in RPMI-1640 with 0.2% FBS for 24 hr. 
Serum-starved medium was used throughout the experiments. Cells were 
treated with PMA (50 ng/㎖) (Sigma-Aldrich) as indicated in each 
experiment. For the inhibition studies, cells were pr treated with media 
containing inhibitors for 30 min before it was replaced with control or PMA-
containing medium. After 24 hr, cells were collected to measure MUC8 
expression.   
4. Immunofluorescence microscopy  
For histological study, cells were washed three times with PBS and 
fixed in 3% paraformaldehyde solution [3% (wt/vol) paraformaldehyde, 0.1 
mM CaCl2 and 0.1 mM MgCl2, pH 7.4, in PBS] for 10 min. The cells were 
then washed three times with PBS, permeabilized in 0.2% Triton®X-
100/PBS for 5 min, and washed three times with PBS. Next, the cells were 
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blocked with 10% normal goat serum (Jackson Immuno Research Labs Inc., 
West Grove, PA, USA) for 1 hr, and then washed with PBS. MUC8 proteins 
were detected using the MUC8 polyclonal antibody and incubated for 24 hr 
at 4 , followed by washes in PBS. This procedure was repeated with an ℃
appropriate fluorescein isothiocyanate (FITC)-conjugated secondary 
antibody (1:100, Jackson Immuno Research labs Inc). Coverslips were 
mounted on the slides with Vectashield Mounting Medium (Vector 
Laboratories Inc., Burlingame, CA, USA), and the slides were examined 
using a Zeiss LSM 510 confocal microscope (Carl Zeiss Inc., NY, USA).  
5. Immunohistochemical staining for AP2α  
The procedures described in this study were approved by the 
Institutional Review Board of the Yonsei University College of Medicine, 
and all participating patients provided informed consent.  Human nasal 
polyps were obtained from patients with chronic sinu tis, and normal nasal 
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mucosa specimens were obtained from healthy subjects. The nasal polyp and 
normal nasal mucosa specimens were fixed with 4% paraformaldehyde for 
24 hr, cryoprotected with 12% and 18% sucrose, and stored in a deep freezer 
until use. The inserts were then divided into 10-㎛ sections, and the frozen 
sections were stained with anti-AP2α antibody. The reaction between the 
antigen and antibodies was detected using peroxidase-conjugated anti-rabbit 
secondary antibody. Negative controls lacked the primary antibody and used 
an irrelevant antibody (purified rabbit IgG were included).  
6. Immunodetection and quantitation of MUC8  
The immuno-dot blotting assay for detection of secreted and 
intracellular mucins produced by cultured cells has been previously 
described in detail38. Briefly, MUC8 mucin was measured using an anti-
human MUC8 antibody. Dilutions of apical secretions, cell lysates, and 
standards were applied to a nitrocellulose membrane, d then incubated 
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with the appropriate primary antibodies, followed by a reaction with 
horseradish peroxidase-conjugated goat anti-rabbit IgG (Jackson, PA, USA). 
The signal was detected by chemiluminescence (ECL kit, Amersham, Little 
Chalfont, UK) and a standard curve was generated by linear regression 
analysis from the concentration. The data are repres nt d as mean ± standard 
deviation (SD) of triplicate cultures from the same experiment.   
7. RNA isolation and reverse transcriptase PCR (RT-PCR)  
Total RNA was extracted from cells using TRIzol® reag nt 
(Invitrogen) following the manufacturer's instructions. Reverse transcription 
reactions were performed with 3 ㎍ of total RNA, random hexamers 
primers (Applied Biosystems, Foster City, CA, USA), AMV reverse 
transcriptase (Applied Biosystems), and RNase inhibtor (Applied 
Biosystems) in a final volume of 25 ㎕. The reverse transcription step ran 
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for 30 min at 42°C and 5 min at 95°C. RT-PCR performed with a MyCycler 
(Bio-Rad, CA, USA) using the primers listed in Table 1.   
8. Real-time quantitative RT-PCR  
TaqMan real-time quantitative RT-PCR analysis of MUC8 gene 
expression was carried out with an Applied Biosystem  7300 Fast Real-
Time PCR system and normalized with respect to β2-microglobulin RNA as 
an endogenous control. The standard curve used for quantification was 
generated with serial 10-fold dilutions of pGEMT-MUC8. The thermocycler 
parameters were 50 °C for 2 min and 95 °C for 10 min, followed by 40 
cycles of 95 °C for 15 s and 60 °C for 1 min. All reactions were performed 
in triplicate. The relative quantity of MUC8 mRNA was obtained using a 
comparative threshold method. Each reaction consisted of 12.5 ㎕ of 2X 
TaqMan PCR Universal PCR master mix (Applied Biosystems), 1 ㎍ of 
cDNA, 800 nM of primers, and 200 nM of TaqMan hybridization probe in a 
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25 ㎕ volume. The probe was labeled with carboxylfluorescein at the 5'-
end and quencher carboxytetramethylrhodamine at the 3'- nd. Analysis of 
AP2α DNA quantity was performed using SYBR Green PCR Core Reagents 
(Applied Biosystems). For reaction, 1 ㎍ of cDNA was placed in a mixture 
containing 2.5 ㎕ of 10X SYBR Green buffer, 3 ㎕ of 25 mM MgCl2, 2 
㎕ of 5 mM dNTP, 0.1 ㎕ of Ampli Taq Gold, 0.2 ㎕ of Amp Erase UNG 
(Applied Biosystems), and 800 nM of primers.  
All primers and probes are listed in Table 1.  
9. Western blot analyses  
NCI-H292 cells were seeded into 6-well plates and cultured for 24 hr 
before serum starvation. After starving in 0.2 % medium for 24 hr, cells 
were treated with 50 ng/㎖ PMA and harvested with 2X lysis buffer (250 
nM Tris-Cl, pH 6.5, 2% SDS, 4% β-mercaptoethanol, 0.02% bromphenol 
blue, and 10% glycerol). Samples (cell lysates) were r suspended in SDS-
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PAGE sample buffer (50 mM Tris-HCl, pH 6.0, 10% glycerol, 2% SDS, 100 
mM β-mercaptoethanol, and 0.1% bromphenol blue), boiled for 10 min, and 
analyzed on 12% SDS-PAGE gels. Resolved proteins were transferred to a 
polyvinylidene difluoride membrane (Millipore, MA, USA). Blots were 
blocked with 5 % skimmed milk in Tris-buffered saline (TBS, 50 mM Tris-
Cl, pH 7.5, and 150 mM NaCl) for 1 hr at room temperature and then 
incubated overnight with primary antibodies (1:1000) in 0.5% Tween 20 in 
TBS (TTBS). After thorough washing with TTBS, the blots were further 
incubated for 1 hr at room temperature with horseradish peroxidase -
conjugated secondary antibodies (1:2000) (Cell Signal ng) in TTBS and then 
visualized by ECL (Amersham Biosciences).  
10. Transient-transfection assay  
For each transfection, NCI-H292 cells were seeded into 6-well plates and 
cultured for 24 hr before transfection. Cells were transfected with 1㎍ of 
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SPRSV-AP2α (AP2α over expression), ㅿ 165 (AP2α-dominant negative), 
or SPRSV-NN (negative control; empty vector) for 24 hr using FuGENE6 
Transfection Reagent (Roche Applied Science, Mannheim, Germany) 
according to the manufacturer's instructions for 24 hr, treated with 50 ng/㎖ 
PMA for 24 hr, and then assayed by RT-PCR, real-time PCR, and western 
blot analysis. 
Plasmids SPRSV-AP2α, ㅿ 165, and SPRSV-NN were kindly provided by 
Dr. Trevor Williams, Yale University (New Haven, CT, USA).  
11. AP2α and ERK1/2 siRNA preparation and transfection  
AP2α siRNA (siAP2α) oligonucleotides (StealthTM siRNA) were 
synthesized by Invitrogen. We screened AP2α mRNA (GenBank 
NM_001032280 and NM_003220) and selected three potential siRNA 
sequences with high values of knockdown probability. The siRNA 
sequences in NM_001032280 started at the 965th, 1238th, and 1594th bases 
 19 
(965: 5'-TCGCAAGATCCTTACTCCCACGTCA-3' 1238: 5'-CCGCATG 
TAGA AGACCCGGGTA TTA-3' 1594: 5'-AGGGAGACGTAAAGC TGC 
CAACGTT-3'). Stealth RNAi Negative Control Duplex (Medium GC, 
Invitrogen) was used as an siRNA negative control (siCon). The siERK1 
(catalog no. sc-29307), siERK2 (catalog no. sc-35335), and siRNA negative 
control (scrambled sequence, catalog no. sc-37007) were purchased from 
Santa Cruz Biotechnology. siRNA transfection into NCI-H292 cells was 
carried out with LipofectamineTM 2000 (Invitrogen) according to the 
manufacturer's instructions. NCI-H292 cells were seded into 6-well plates 
one day before transfection and co-transfected with15 nM of each siRNA 
when the cells reached 30-50% confluence.  
12. Transient Transfection and Luciferase Analysis  
 A series of constructs of MUC8 promoter gene were reported in our 
previous study39. NCI-H292 cells were transiently transfected with pGL3-
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basic, pGL3-MUC8 (-1644/+ 87), pGL3-MUC8 (-1190/+ 87), pGL3-MUC8 
(-973/+ 87), and pGL3-MUC8 (-549/+ 87) constructs using a FuGENE6 
Transfection Reagent (Roche Applied Science) according to the 
manufacturer’s instructions, incubated for 48 h, trea ed with 50 ng/㎖ of 
PMA for 24 hr, harvested, and assayed for luciferas ctivity using a 
luciferase assay system (Promega, WI, USA) according to the 
manufacturer’s instructions. β-galactosidase activity was also assayed to 
standardize sample transfection efficiencies.  
13. Chromatin immunoprecipitation assay (ChIP assay)  
Approximately 2X109 NCI-H292 cells in 150-mm dishes were treated 
with PBS containing 1% formaldehyde for 10 min, washed twice with PBS, 
and fixed with 125 mM glycine at room temperature for 5 min. The cells 
were rinsed twice with PBS and resuspended in 1 ml of solution A (10 mM 
HEPES, pH 6.5, 0.25% Triton X-100, 10 mM EDTA, and 0.5 mM EGTA) 
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by pipetting. After a short spin (5 min at 3000 rpm), the pellets were 
resuspended in solution B (10 mM HEPES, pH 6.5, 200 mM NaCl, 1 mM 
EDTA, and 0.5 mMEGTA) containing protease inhibitors by vigorous 
pipetting to extract nuclear proteins. After centrifugation at 4,000 rpm for 5 
min, the nuclear pellets were resuspended in immunoprecipitation buffer (10 
mM EDTA, 50 mM Tris-HCl, pH 8.1, 1% SDS, and 0.5% Empigen BB) 
containing protease inhibitors and sonicated to break the chromatin into 
fragments with an average length of 0.5-1 kb. The following antibodies were 
used in the assay: 2 ㎍ of anti-AP2α antibody and 2 ㎍ of goat anti-rabbit 
IgG as a negative control. The putative AP2α site (-2496 to -2297 and -2796 
to -2596) and control (-5830 to -5630) primers used for ChIP analysis are 
listed in Table 1.  
14.  Electromobility shift analysis  
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PMA-treated NCI-H292 cells were washed with ice-cold PBS and 
pelleted. Pellets were resuspended in cell homogenization buffer (10 mM 
HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, and 0.5 
mM phenylmethylsulfonylfluoride), incubated for 10 min on ice, and 
centrifuged. Cells were then resuspended in cell homogenization buffer 
containing 0.05% (V/V) Nonidet P-40 and then homogeniz d. Next, nuclei 
were pelleted and resuspended in cell resuspension buffer [40 mM HEPES, 
pH 7.9, 0.4 M KCl, 1 mM dithiothreitol, 10% (V/V) glycerol, 0.1 mM 
phenylmethylsulfonylfluoride, 0.1% (W/V) aprotinin, and 0.3 M NaCl]. This 
nuclear extract was then centrifuged at 24,000 rpm for 15 min at 4 °C, and 
the supernatant was aliquoted and stored at -70 °C. For the electromobility 
shift assay, oligonucleotides corresponding to the MUC8 AP2α sequence (5'- 
GTTCTGGGGC CACTTCCCTGGCCACCG - 3') were synthesized, 
annealed, and end-labeled with [γ-32P] ATP using T4-polynucleotidekinase 
(Promega). Ten micrograms of nuclear extract were incubated at room 
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temperature for 30 min with the 32P-labeled AP2α probes in binding buffer 
(Promega). Oligo-nuclear protein complexes were separated from the probes 
by electrophoresis through 6% nondenaturing polyacryl mide gels in 0.5X 
Tris borate- EDTA (TBE) buffer. Supershift experiments were conducted 
using 2 ㎍ of anti-phospho-AP2α antibody (Cell Signaling). The gels were 
dried and autoradiographed on a PhosphorImager.  
15. Preparation of lentivirus shRNA  
The complete details of the construction of the pLL3.7 lentivirus vector 
are described online (http://web.mit.edu/jacks-lab/index.html). AP2α shRNA 
and mutant AP2α shRNA (negative control) target sequences were 5'- 
GGGTATTAACATCCCAGATCA-3' and 5'- GGATAGTACCAGCCTAGC 
TCC -3' (italic letters represent mutated bases), respectively, which have no 
significant similarity to other AP2 family mRNAs. 293T cells were seeded 
and cultured for 24 hr until 80-90% confluency and co-transfected with 
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pLL3.7 and packaging vectors. The resulting supernatant was collected after 
48 hr. We recovered the virus after ultracentrifugation for 5 hr at 25,000 rpm 
in a Beckman SW28 rotor and resuspended it in PBS (200 ㎕). Titers were 
determined by infecting 293T cells with serial dilutions of concentrated 
lentivirus. We determined the GFP expression of infected cells by flow 
cytometry 48 hr after infection; the titer was approximately 5 x 105 viral 
particles/㎕. 
Statistical Analysis  
The statistical significance of the difference between the groups was 
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1. AP2α expression in normal nasal mucosa and nasal polyp  
We first examined the level of AP2α expression in normal nasal 
 26 
mucosa and nasal polyp tissue by western blot analysis. AP2α was 
overexpressed in all nasal polyps and weakly expressed in the normal nasal 
mucosa (Fig. 1A). The mean AP2α expression level was 21-fold higher in 
nasal polyp tissue than in normal nasal mucosa (Fig. 1B). We also 
investigated AP2α expression in normal nasal mucosa and nasal polyps b  
immunohistochemical analysis (Fig. 1C). AP2α was highly expressed 
throughout the epithelium of nasal polyp tissue andminimally expressed in 
normal nasal mucosa.  
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Figure 1. AP2α expression in normal nasal mucosa and nasal polyp 
Normal nasal mucosa and nasal polyps were examined for AP2α expression levels. A 
representative western blot analysis of AP2α protein in normal nasal mucosa and nasal polyp 
tissue from seven patients is shown. Each lane contains he expression of β-actin used as a 
loading control to normalize the AP2α protein levels in each sample (A). Graph of 
densitometric analysis. AP2α protein band intensities were normalized by β-actin values. 
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Mean ± SD AP2α expression of all the nasal polyp samples normalized to β-actin and 
expressed as fold intensity with respect to the normal nasal mucosa (B). 
Immunohistochemical staining of AP2α expression in normal nasal mucosa and nasal polyps 
(C). Immunostaining of AP2α in normal nasal mucosa (a), and nasal polyp tissue (b). 
Immunostaining of IgG (negative control) in normal n sal mucosa (c), and nasal polyp tissue 
(d).   
 
2. PMA up-regulates MUC8 gene expression in NCI-H292 cells  
PMA has been suggested as an inducer of MUC2, MUC5AC and 
MUC5B gene expression 6, 8-13. In this study, we investigated the effect of 
PMA on MUC8 gene expression. NCI-H292 cells were treated with 5 o 50 
ng/㎖ PMA for 24 hr. PMA induced MUC8 gene expression in a dose-
dependent manner (Fig. 2A). Based on this observation, 50 ng/㎖ of PMA 
was used for all subsequent experiments. In addition, o determine whether 
PMA induced MUC8 gene expression in a time-dependent manner, we 
examined MUC8 gene expression at different time points (Fig. 2B). 
Stimulation with 50 ng/㎖ of PMA led to a significant time-dependent 
increase (with a peak at 6–24 hr after PMA stimulation). The up-regulation 
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of MUC8 after PMA treatment was also observed in NCI-H292 cells using 
immunocytochemistry. MUC8 expression was observed in the cytoplasm of 
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Figure 2. Effects of PMA on MUC8 gene expression NCI-H292 cells. 
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Confluent cells were treated with increasing doses of PMA (5, 10, 20, and 50 ng/ml) for 24 hr 
(A). Confluent cells were treated with PMA (50 ng/ml) for 3, 6, 12, 18, or 24 hr (B). Total 
RNA was prepared and subjected to RT-PCR (upper panel) d quantitative real-time RT-PCR 
(lower panel) with β2-M (beta2-microglobulin) as an internal control. Twenty-four hours after 
treatment with PMA (50 ng/ml), cells were fixed and stained with anti-MUC8 antibody (C). 
 
3. AP2α is involved in PMA-induced MUC8 gene expression.  
We next evaluated AP2α mRNA expression in NCI-H292 cells 
stimulated with PMA for 10 min to 24 hr. AP2α mRNA expression levels 
peaked at 1 hr and then decreased after 12 hr (Fig.3A). Western blot 
analysis of AP2α showed a marked increased in AP2α protein levels after 1 
hr of treatment with PMA that decreased after 6 hr (Fig. 3B).  
To determine whether AP2α plays a role in MUC8 gene expression, 
siRNA was used to knockdown AP2α in NCI-H292 cells. For this purpose, 
NCI-H292 cells were transiently transfected with AP2α siRNA and negative 
control siRNA. The effects of the siRNA were analyzed by western blot 
analysis and RT-PCR. Quantitative real-time RT-PCR showed that cells 
transfected with AP2α siRNA, but not control siRNA demonstrated reduced 
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MUC8 gene expression (Fig. 3C). This finding indicates hat AP2α is 


























































Figure 3. Involvement of AP2α in PMA-mediated MUC8 gene 
expression in NCI-H292 cells. Confluent cells were stimulated with PMA for the 
indicated times, and total cell lysates were collected for AP2α RT-PCR (A) and western blot 
analysis (B) were performed. Cells were transiently transfected with either siAP2α or control 
siRNA. Twenty-four hours after transfection, the transfected cells were stimulated with PMA 
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for 3 hr (for Western blot analysis), 1 hr (for RT-PCR), and 24 hr (for quantitative real-time 
RT-PCR) (C). The figures shown are representative of three independent experiments. 
 
4. Involvement of MEK1-ERK1/2 MAPK in induction of MUC8 and 
AP2α expression by PMA  
To determine which MAPK subfamily members are actively involved 
in PMA-induced MUC8 gene expression, the phosphorylation status of 
major MAPK members were evaluated by western blotting using phospho-
specific antibodies. As shown in Fig. 4A, both MEK1 and ERK1/2 MAPK 
were maximally activated at 10 min, and this effect decreased after 30 and 
20 min, respectively. Both c-Jun N-terminal kinase (JNK) and p38 were 
weakly activated at 10 min by PMA. Thus, it appears that stimulation by 
PMA activated the MEK1, ERK1/2, JNK, and p38 pathways in NCI-H292 
cells. Because PMA significantly increased MUC8 gene expression and 
MEK1, ERK1/2, and JNK activity, we investigated whet r PMA-induced 
MUC8 gene expression is involved in the MAP kinase pathwy.  To 
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ascertain the involvement of MEK1, ERK1/2, and JNK in PMA-induced 
MUC8 gene expression, cells were exposed to PD98059 (a MEK1 inhibitor), 
SP600125 (a JNK inhibitor), or SB-239063 (a p38 inhibitor) before PMA 
treatment. Pretreatment with PD98059 for 1 hr clearly inhibited PMA-
induced ERK1/2 MAPK and significantly suppressed PMA-induced MUC8 
gene expression in a dose-dependent manner (Fig. 4B). In this study, SP 
600125 and SB-239063 pretreatment failed to inhibit PMA-induced MUC8 
gene expression (data not shown). To further confirm the results obtained 
with PD98059, NCI-H292 cells were transiently transfected with ERK1, 
ERK2, or negative control siRNA. In this study, PMA-induced ERK1/2 
phosphorylation was lower in ERK1/2 siRNA transfected cells, which also 
significantly suppressed PMA-induced MUC8 gene expression (Fig. 4C). 
These results demonstrate that both MEK1 and ERK1/2 MAPK are essential 
for PMA-induced MUC8 gene expression in NCI-H292 cells.  
Furthermore, PMA-induced AP2α expression was significantly 
 34 
suppressed in cells treated with either PD98059 or transfected with ERK 1 
and 2 specific siRNA. As shown in Figure 4D, PD98059 reduced the AP2α 
protein induced by PMA in a dose-dependent manner. Twenty-four hours 
after siRNA transfection, the cells were stimulated with PMA for 3 hr and 
then harvested for RNA. AP2α mRNA expression was suppressed by 
transfection with ERK1/2 siRNA but not negative contr l siRNA (Fig. 4E). 
These results indicate that both MEK1 and ERK1/2 are the main signaling 
molecules responsible for AP2α activation and MUC8 gene expression in 
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Figure 4. Involvement of MEK1-ERK1/2 MAPK in induction of MUC8 
and AP2α expression by PMA. Confluent cells were treated with PMA for the 
indicated periods of time (10, 20, 30, or 60 min), and 30 ㎍/lane of total cell lysate protein 
was subjected to western blot analysis. The blotted proteins were probed with antibodies 
against phosphorylated or non-phosphorylated forms of MAP kinases (MEK1-ERK1/2, JNK, 
and p38) and α-tubulin (as a control) as indicated (A). Confluent cells were pretreated for 1 hr 
with PD98059 (20, 50, and 100 uM) and then stimulated with PMA for 24 hr prior to the 
extraction of total RNA for quantitative real-time RT-PCR. Pretreated cells were stimulated 
for 10 min (to detect the phosphorylation of ERK1/2; B, upper panel) or 3 hr (to detect the 
activation of AP2α, D) with PMA prior to the collection of cell lysate for western blot 
analysis. NCI-H292 cells were transiently transfected with siERK1, siERK2, or control 
siRNA (siCon) and stimulated with PMA for 10 min (to detect the phosphorylation of 
ERK1/2; C, upper panel) or 3 hr (to detect the activ tion of AP2α, E) prior to western blot 
analysis. Transfected cells were stimulated with PMA for 24 hr prior to quantitative real-time 
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RT-PCR (C and D, lower panel). The figures shown are representative of three independent 
experiments. 
5. Activation of PKC mediates PMA-induced MUC8 gene expression  
To identify the molecules involved in the upstream signaling of ERK1/2 
MAPK in PMA-induced MUC8 gene expression, we investigated the role of protein 
kinase C (PKC) in the initiation of PMA-induced MUC8 gene expression. PMA has 
been reported to induce activation of PKC in several cell types27, 29. PKC is known 
to regulate ERK1/2 activity27, 29, and 34. To determine the role of PKC, NCI-H292 cells 
were pretreated with 10 µM RO-31-8220 (a PKC inhibitor) for 1 hr before PMA 
stimulation, followed by western blot analysis with anti-phospho-ERK1/2 antibody 
(Fig 5A) or quantitative real-time RT-PCR for MUC8 gene expression (Fig 5B). In 
this study, RO-31-8220 significantly inhibited PMA-induced phosphorylation of 
ERK1/2 and MUC8 gene expression. These results show that PMA-induced ERK1/2 
















































Figure 5. Activation of PKC is required for PMA-induced MUC8 gene 
expression in NCI-H292 cells. Confluent cells were pretreated for 1 hr with RO-31-
8220 (10 µM) and then stimulated for 10 min with PMA prior to the collection of total cell 
lysates for western blot analysis using anti-phosph-ERK1/2 antibody (A). After 24 hr of 
stimulation of inhibitor-pretreated cells, total RNA was isolated, and MUC8 gene expression 
was measured using quantitative real-time RT-PCR (B). The figures shown are representative 
of three independent experiments.  
 
6. Overexpression of AP2α up-regulates MUC8 gene expression in NCI-
H292 cells.   
To examine the functional role of AP2α in MUC8 gene expression, we 
used wild-type AP2α or mutant AP2α (dominant negative, deletion form of 
N-terminal amino acid) expression vectors in NCI-H292 cells. Efficient 
transfection of constitutively active AP2α expression (efficient expression of 
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AP2α) was confirmed by detection of wild-type AP2α (52 kDa) and mutant 
type AP2α (30 kDa) proteins (Fig. 6A). Overexpression of thewild-type 
AP2α gene (confirmed by RT-PCR) affected the level of MUC8 mRNA 
(measured by quantitative real-time RT-PCR), suggesting that AP2α activity 
is required for MUC8 gene expression. We also determined the effect of the 
AP2α dominant negative mutant in PMA-treated NCI-H292 cells. The 
mutant type AP2α vector has a DNA binding/dimerization domain, but no a 
transcriptional activation domain. Expression of the mutant type AP2α gene 
in the cells was confirmed by RT-PCR, and its inhibitory effect decreased the 
level of MUC8 gene expression (measured by quantitative real-time RT-PCR, 
Fig. 6B). Next, we evaluated the expression level of the MUC8 gene induced 
by wild type AP2α under the influence of the inhibitor PD98059. Twenty-
four hours after transient transfection with wild type AP2α, NCI-H292 cells 
were pre-treated with the inhibitor for 1 hr and stimulated with PMA. PMA-
induced AP2α and MUC8 gene expression were inhibited by PD98059, but 
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not in wild-type AP2α transfected cells (Fig. 6C). These findings indicate 
that transfected AP2α remains in the activated state downstream of the 
PKC/MEK pathway and influences MUC8 gene expression. Taken together, 
these results emphasize the key roles of AP2α in the transcription of MUC8 
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Figure 6. Overexpression of AP2α up-regulates MUC8 gene expression 
in NCI-H292 cells. NCI-H292 cells were transiently transfected with basic (empty), 
wild-type, or mutant ( 165, N terminal 165 aa deleted form) △ AP2α expression vectors. 
Western blot analysis of AP2α expression in NCI-H292 cells after gene delivery (A). Twenty-
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four hours after transient transfection with the expr ssion vector, cells were stimulated with 
PMA, and then total RNA was prepared for RT-PCR andquantitative real-time RT-PCR (B). 
Twenty-four hours after transient transfection of the expression vector, cells were pretreated 
with PD98059 for 1 hr, and then cells were stimulated with PMA for quantitative real-time 
RT-PCR (C). The figures shown are representative of three independent experiments. 
 
7. AP2α is involved in the induction of MUC8 promoter activity by PMA. 
 
Systematically deleted MUC8 5’-flanking regions spanning from +87 
bp to -1,644 bp, -1,190 bp, - 807 bp, and - 662 bp relative to the transcription 
initiation site were generated and cloned into the promoter less pGL3 vector. 
All transiently transfected MUC8 promoter deletion constructs all showed no 
significant increased activity upon treatment with PMA (Fig 7A).   
To further study the potential transcription factors involved in PMA-
induced MUC8 expression, the MUC8 promoter (upstream of -1644) was 
analyzed for putative transcription factor binding sites with the PATCHTM 
database (http://gene-regulation.com) and Genomatix/MatInspector database 
(http://genomatix.de). There are two putative AP2α binding sites (-2698/-
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2684 and -2476/-2464) on the MUC8 promoter. To assess whether AP2α 
directly regulates MUC8 gene expression, we investigated which regions 
(transcription factor-binding sites) of the MUC8 gene promoter were 
activated by PMA-induced AP2α. Since the regions -2496 to -2297 and -
2796 to -2596 contain putative AP2α binding sites, we performed ChIP 
assays using specific primers for these regions. We also used the region -
5830/-5630 as a negative control (Fig. 7B). Twenty-four hours after 
transfection with AP2α siRNA or control siRNA, cells were treated with 
PMA for 3 hr. After purification of the DNA in the immunoprecipitate, the 
abundance of genomic DNA containing a promoter was determined by PCR 
amplification using sequence-specific primer pairs.  The ChIP assays 
clearly showed that AP2α directly binds to the MUC8 promoter (-2496/-
2297). AP2α was recruited to at the -2496/-2297 region of MUC8 promoter 
upon PMA treatment. When AP2α expression was knocked down by AP2α 
siRNA, but not control siRNA, the recruitment of AP2α on -2496/-2297 site 
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was reduced. Real-time PCR was performed with -2496/-2297 region 
primers (Fig. 7C). Anti-rabbit IgG, the negative contr l, did not yield any 
signals, indicating the assay specificity. Input chromatins were also used in 
these assays to indicate that equal amounts of cell lysates were used from 
PMA-treated cells. Based on these results, we conclude that PMA-induced 
AP2α protein is strongly recruited to the chromatin regions of the AP2α 
binding site of the MUC8 promoter (-2496/-2297).  Consistent with this 
conclusion, the binding of AP2α to the MUC8 promoter was further 
confirmed by electromobility shift assays using the nuclear extracts of PMA-
treated NCI-H292 cells. The nuclear extract binding activities of MUC8-
specific AP2α oligonucleotides increased remarkably in response to PMA 
(Fig. 7D). To identify the specific AP2α binding complex, competition and 
supershift analyses were performed using 50-fold excesses of non-
radiolabeled AP2α oligonucleotide (cold) and anti-phospho-AP2α antibody, 
respectively. The intensity of specific band was selectively reduced by a 
 43 
consensus AP2α competitor and anti-phospho-AP2α antibody. These results 
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Figure 7. AP2α is involved in the induction of MUC8 promoter activity 
by PMA. NCI-H292 cells were transiently transfected with deletion constructs as indicated 
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and then treated with PMA before harvesting for luciferase assay (A). ChIP analysis was 
performed with chromatin from NCI-H292 cells. Twenty-four hours after cells were 
transfected with siAP2α or control siRNA, they were stimulated with PMA for 3 hr. Cross-
linked protein-DNA complexes were immunoprecipitated using anti-AP2α antibody or goat 
anti-rabbit IgG (negative control). The immunoprecipitated chromatin was analyzed with 
PCR using primers specific to the indicated site. Input chromatin represents a portion of the 
sonicated chromatin before immunoprecipitation (B). Real-time PCR was performed with -
2496/-2297 region primers (C). The figures shown are representative of three independent 
experiments. Nuclear protein extract from PMA-treated NCI-H292 cells was subjected to an 
electromobility shift assay (D). Nuclear proteins were incubated with 50-fold excesses of cold 
probe for the competition assay and preincubated with anti-phospho- AP2α antibody for 
supershift before the electromobility shift assay.   
 
 
8. Effects of PMA on MUC8 gene expression in NHNE cells.  
We examined whether MUC8 is also expressed in PMA-induced normal 
human nasal epithelial cells (NHNE). NHNE cells were treated with 2 to 50 
ng/㎖ PMA for 12 hr. The level of MUC8 gene expression was gradually 
increased and reached a plateau at 10 ng/㎖, being increased by 4.3 fold 
(Figure 8A). Based on this observation, 10 ng/㎖ of PMA was used for all 
subsequent experiments in NHNE cells. In addition, t  determine whether 
PMA induced MUC8 gene expression in a time-dependent manner, we 
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examined MUC8 gene expression at different time points (Fig. 8B). 
Stimulation with 10 ng/㎖ of PMA led to a significant time-dependent 
increase. Phosphorylation of ERK1/2, AP2 α, and MUC8 gene expression by 
PMA were inhibited by pretreated with RO-31-8220 and PD98059 (Fig 8C 
and D), implicating PKC and MEK-ERK1/2 dependent MUC8 gene 
































































































































































Figure 8. Effects of PMA on MUC8 gene expression in NHNE cells. 
NHNE cells were treated with increasing doses of PMA (2, 5, 10, 20, and 50 ng/ml) for 12 hr 
(A). NHNE cells were treated with PMA (10 ng/ml) for 0.2, 0.5, 1, 3, or 12 hr (B). Total RNA 
was prepared and subjected to RT-PCR (upper panel) d quantitative real-time RT-PCR 
(lower panel) with β2-M (beta2-microglobulin) as an internal control. NH E cells were 
pretreated for 1 hr with RO-31-8220 (10 µM) or PD98059 and then stimulated for 10 min 
with PMA prior to the collection of total cell lysates for western blot analysis using anti-
phospho-ERK1/2 antibody (C). After 12 hr of stimulation of inhibitor-pretreated cells, total 
RNA was isolated, and MUC8 gene expression was measured using quantitative real-time RT-
PCR. The figures shown are representative of three independent experiments. 
 
9. Silencing endogenous AP2α efficiently blocks MUC8 gene expression 
in nasal polyp epithelial cells    
To assess the role of AP2α in MUC8 gene expression in nasal polyp 
epithelial cells, we used lentivirus shRNA to delet AP2α from the cells. 
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Because the AP2α siRNA sequences used in NCI-H292 cells were effectiv , 
we applied the partially overlapped siRNA sequences to the lentivirus 
shRNA oligo. Nasal polyp epithelial cells were infect d with shAP2α 
lentivirus or control shRNA (mutant form of shAP2α) lentivirus before 
differentiation. We determined whether transgene expression could be 
maintained throughout the differentiation processes in nasal polyp epithelial 
cells. Seven days after the differentiation of cells, a GFP expression image 
was taken. As shown in Fig. 9A, GFP expression was easily detected in nasal 
polyp epithelial cells. We confirmed by western blot analysis that 
endogenous AP2α expression was significantly suppressed by shAP2α, 
whereas control shRNA did not affect endogenous AP2α expression (Fig. 9B, 
upper panel).  
We next examined whether AP2α knockdown affects MUC8 gene 
expression in nasal polyp epithelial cells. Seven days after differentiation, 
shRNA-infected nasal polyp epithelial cells were prpared for quantitative 
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real-time RT-PCR and dot-blot analysis. shAP2α markedly reduced 
endogenous MUC8 gene expression (Fig. 9B, lower panel), and dot-blot 
analysis with anti-MUC8 antibody on supernatants and lysates from 
harvested cells revealed that shAP2α decreased endogenous MUC8 
expression significantly, while control shRNA did not (Figs. 9 C and D). 
These results suggest that endogenously expressed AP2α is involved in 


































































































































Figure 9. Lentivirus-mediated shAP2α efficiently blocks MUC8 gene 
expression in nasal polyp epithelial cells. Lentivirus provides efficient delivery of 
exogenous genes into nasal polyp epithelial cells. Nasal polyp epithelial cells were infected 
with wild type AP2α lentivirus or mutant type shRNA lentivirus and then differentiated. 
Seven days after differentiation of cells, GFP exprssion and phase contrast images of the 
same area were taken, and the cells were lysed (7 d after differentiation) for western blot 
analysis of AP2α (A ). Seven days after differentiation, total RNA was prepared for real-time 




Previous studies have suggested that MUC8 is an important mucin gene 
because inflammatory mediators upregulate MUC8 gene expression in in 
vitro culture, and MUC8 gene expression is upregulated in human nasal 
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polyp epithelium. Extensive work has shown that MUC8 may play an 
important role in the pathogenesis of mucus hypersecretion in polyp 
epithelium. Lopez-Ferrer et al. report that MUC8 protein is overexpressed in 
human bronchial epithelium40. Moreover, Martinez-Antonet et al. indicate 
that the MUC8 protein is highly expressed in both nasal polyp epithelium 
and submucosal glands. At the same time, the molecular mechanism of 
MUC8 gene overexpression in nasal polyp epithelium remains poorly 
understood. In this study, we first observed AP2α expression in nasal polyp 
tissue and normal nasal mucosa. Since the levels of AP2α were much greater 
in nasal polyp epithelium, we sought to ascertain whether increased levels of 
AP2α might lead to MUC8 gene expression. We found that PMA increased 
MUC8 expression in NCI-H292 cells through PMA-activated AP2α. In 
addition, we showed that AP2α mRNA and protein were increased by PMA 
in a dose- and time-dependent manner, although several studies have 
suggested that phorbol esters, along with cyclic AMP, induce AP2α activity 
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independent of protein synthesis41. In contrast, retinoic acid induces AP2α 
activity by increasing AP2α mRNA levels in human teratocarcinoma cells42, 
43. These different patterns of AP2α activity may be dependent on a cell 
type- and tissue-specific regulation of PMA. Furthe work is necessary to 
explore these regulatory mechanisms. Specific knockd wn of AP2α with 
siRNA significantly reduced PMA-induced MUC8 gene expression (Fig. 
3C), showing that AP2α activation is required to induce MUC8 gene 
expression in human airway epithelial cells.   
PKC-mediated activation of the MEK/ERK MAPK signaling pathway 
and its role in regulating mucin gene expression have been studied27, 34, 44, 45, 
but the exact order of events leading to AP2α activation has not been fully 
elucidated. To identify which MAP kinase pathways were involved in 
MUC8 and AP2α expression, various kinase inhibitors were tested for their 
ability to reduce MUC8 and AP2α transcription. Only activation of MEK-
ERK 1/2 MAPK was required for PMA-induced MUC8 and AP2α gene 
 52 
expression, although p-38 and JNK MAPK were phosphorylated by PMA 
(Fig 4). Specific knockdown of ERK1 and ERK2 with siRNA completely 
blocked PMA-induced MUC8 and AP2α gene expression as compared with 
the control, showing that the ERK1/2 MAPK activation is required to induce 
AP2α activation and MUC8 gene expression in NCI-H292 cells. To confirm 
the involvement of AP2α in mediating the effects of PMA, we transfected 
cells with a dominant-negative form of AP2α and showed that PMA-induced 
MUC8 gene expression was significantly inhibited by dominant-negative 
AP2α. In addition, overexpression of wild-type AP2α significantly increased 
MUC8 gene expression (Fig. 5). These findings indicate that he expression 
level of MUC8 gene is regulated by AP2α.  
In the present study, our results show that the -2496 to -2297 region of 
the MUC8 promoter is involved in the response to PMA and that e AP2α 
binding site in the -2476/-2464 region of the MUC8 promoter is important 
for MUC8 gene up-regulation by PMA.  
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We also tested the effect of PMA on MUC8 gene expression in NHNE 
cells (Fig.8). In this study, we showed that the results in both NHNE and 
NCI-H292 cells were the same.  
To date, the positive influence of AP2α transcription factor has been 
reported in mammary epithelial cells. A number of studies have reported that 
AP2α transcription factor has tumor suppressor activity. AP2α activity is of 
prognostic relevance in invasive breast cancer. The loss of AP2α expression 
may be associated with malignant transformation and tumor progression in 
malignant melanoma46-49.  In addition, re-expression of AP2α in breast 
cancer and metastatic melanoma cells results in enhanced chemosensitivity, 
decreased tumorigenicity, and inhibited metastatic potential35, 50. Although 
much is known about the positive regulation of AP2α genes, we 
demonstrated in this study that AP2α transcription activity was required for 
MUC8 gene expression, suggesting that AP2α may induce inflammation in 
airway epithelium. Furthermore, to examine whether ndogenously 
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expressed MUC8 in nasal polyp epithelial cells is an AP2α mediated 
transcription, we used lentivirus shRNA to delete AP2α from nasal polyp 
epithelial cells. This method is highly efficient, and because the lentivirus 
integrated into the cell genome51, 52, AP2α shRNA was permanently 
expressed, leading to long-term knockdown of the AP2α protein. After 
shRNA-mediated knockdown of AP2α, MUC8 expression was significantly 
lower in nasal polyp epithelial cells.    
 
In summary, PKC-ERK1/2 MAPK signaling is essential for PMA-
induced MUC8 gene expression, and activation of AP2α is required for the 
intracellular mechanisms that mediate MUC8 gene expression. AP2α was 
overexpressed in nasal polyp epithelial cells, and plays an important role in 
MUC8 expression. From these results, we conclude that AP2α plays a 
crucial role in the expression of the MUC8 gene in human airway epithelial 
cells.    
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V. CONCLUSION  
In conclusion, PKC-ERK1/2 MAPK signaling is essential for PMA-
induced MUC8 gene expression, and AP2α plays a crucial role in the 
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호흡기 상피 세포에서 AP2α에 의한 MUC8 발현의 
조절  
(지도교수 윤 주 헌) 
 
연세대학교 대학원 의과학과 
문욱열 
고분자 단백질체인 Mucin은 mucus의 매우 중요한 성분이며 이러한 
mucus의 과 분비는 여러 가지 만성 호흡기 질환의 공통적인 특징
이다. MUC8은 호흡기 mucus의 대표적인 mucin으로 nasal polyp 상
피 세포에 과량 분포되어 있는 것이 보고되어 왔다. 그러나, 이러
한 MUC8 유전자 발현이 유도되는 기작은 아직까지 잘 밝혀지지 
않았다. 기도 상피세포 종류인 NCI-H292 세포에 Phorbol 12-
myristate 13-acetate (PMA)를 처치하면 MUC8 유전자 발현이 증가한
 71 
다. 따라서, 우리는 염증 유도 물질인 PMA로 유도된 MUC8 유전
자 발현에 어떠한 신호 전달 물질이 관여 하는지를 연구하였다. 이 
실험에서, 우리는 MUC8 유전자 발현이 protein kinase C (PKC) 와 
mitogen activating protein-ERK kinase (MAKP)을 통해 이루어 진다는 
것을 알았다. RO31-8200 (PKC 억제물질)과 PD98059 (MEK-1 억제 
물질) 그리고 ERK1/2 siRNA를 이용한 실험에서, PMA로 유도된 
MUC8 유전자뿐만 아니라 activator protein-2alpha (AP2α) 발현까지 
모두 현저하게 줄어든 것을 확인 하였다. 따라서, AP2α에 대한 역
할을 확인하기 위해 AP2α에 대한 siRNA를 제작 하여 실험하였고, 
그 결과 PMA에 의해 증가되었던 MUC8 유전자가 현저하게 줄어
든 것을 확인 할 수 있었다. Dominant negative 형태의 AP2α 과 발
현이 PMA로 유도 되었던 MUC8 유전자 발현을 억제 시킨다는 것
을 관찰하였고, wild 형태의 AP2α 과 발현은 MUC8 유전자의 증가
를 유도 한다는 것을 관찰하였다. 또한, MUC8 유전자 발현을 조절
할 수 있는 MUC8 promoter내의 AP2α 결합 부위를 밝혀냈다. 마지
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막으로 lentivirus를 이용한 AP2α 의 siRNA 실험을 nasal polyp 상피 
세포를 이용하여 수행하였고, 그 결과 AP2α가 MUC8 유전자 발현
에 매우 중요한 역할을 한다는 사실을 증명하였다. 결론적으로, 기
도상피 세포내의 MUC8 유전자 발현은 PKC-MEK-ERK1/2-AP2α를 
통한 기작으로 이루어 진다는 사실을 밝혀냈다.   
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